Alvotech and Abdi Ibrahim partner on biosimilars in Turkey

Icelandic biosimilars company Alvotech and leading Turkish drugmaker Abdi Ibrahim have entered into an exclusive partnership for the manufacturing and commercialization of Alvotech’s biosimilar portfolio for the Turkish market, the companies announced today.

Under the partnership, Alvotech will be responsible for the development and joint supply of multiple high value biosimilar assets from its current product pipeline, while Abdi Ibrahim will be responsible for joint manufacturing from its own facility, along with the registration and commercialization of these assets in Turkey.

Alvotech’s initial pipeline contains several biosimilar monoclonal antibodies and fusion proteins aimed at treating severe immune, inflammatory conditions, that improve the quality of life for patients around the world. Alvotech’s fully vertically integrated platform can support new products each year and over time create a substantial portfolio of high quality, high value products.

Robert Wessman, Alvotech’s founder and chairman said: “We are very proud to announce our strategic alliance with Abdi Ibrahim, a leading company in the Turkish pharmaceutical market. We strongly believe that in combining Alvotech’s high value biosimilars portfolio and significant manufacturing capacity with Abdi Ibrahim’s deep market experience and local manufacturing capacity, will benefit patients in Turkey who will get better access to high-quality biosimilars.”